EQT is pleased to announce that the EQT Healthcare Growth Strategy and the EQT Growth Fund have agreed to acquire a majority stake in CluePoints  with meaningful reinvestment from the management team and existing shareholders Summit Partners and Clinimetrics SA, which was also a...

Anglo-Swedish drugmaker AstraZeneca  on Wednesday announced the global withdrawal of its Covid-19 vaccine Vaxzevria. Demand for AstraZeneca’s Vaxzevria vaccine began tapering off as new vaccines tailored to specific Covid variants have emerged, the pharmaceutical company said in a...

  AbbVie Inc. and Landos Biopharma, Inc.  had announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead...

ONO Pharmaceutical and Deciphera Pharmaceuticals had announced that on April 29, 2024 ,ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer...

Eli Lilly and Company  and Nexus Pharmaceuticals, today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry. “The acquisition of this state-of-the-art facility underscores our...

Anglo-Swedish drugmaker AstraZeneca  on Wednesday announced the global withdrawal of its Covid-19 vaccine Vaxzevria. Demand for AstraZeneca’s Vaxzevria vaccine began tapering off as new vaccines tailored to specific Covid variants have emerged, the pharmaceutical company said in a...

US multinational pharmaceutical company Bristol Myers Squibb is to acquire radiological drug developer RayzeBio, Inc. for approximately $4.1bn. Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, representing a premium of 104 percent to the stock’s last close....

AstraZeneca had announced the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. As a result of...

Gilead has agreed to acquire CymaBay, a Newark, California-based clinical-stage bio/pharmaceutical company, for $4.3 billion. CymaBay’s lead candidate is seladelpar, an oral drug for treating primary biliary cholangitis (PBC), a rare, chronic, cholestatic liver disease. Under the...

Kyowa Kirin has agreed to acquire gene therapy developer Orchard Therapeutics for up to $477.6 million, to develop several biopharmaceutical candidates in areas including oncology and autoimmune diseases. Under the terms of the agreement, Kyowa will acquire Orchard for $16 per...